Walgreens back in the long-term care market, sort of

Share this article:

With more vendors targeting the hospice market, two drug giants appear ready to face off. Walgreens left the institutional-pharmacy business in 2010, of which hospice pharmacy is a part, in a deal with Omnicare. Walgreens traded the unit for Omnicare's home-infusion business. Since then, Omnicare has been the market leader for hospice drugs. So why the strategy change for Walgreens? One reason is that hospice remains a largely fragmented market. It also isn't dominated by pharmacy benefit managers. Walgreens sees these factors as key advantages as it attempts to resettle in this part the long-term care sector. By some estimates, the institutional pharmacy market — including skilled care, hospice and assisted living — is currently worth about $14 billion a year.

Share this article:
close

Next Article in Products

More in Products

Malnutrition remains issue

Identifying malnutrition in patients upon admission to a hospital is a low-cost way to improve patient outcomes and reduce readmissions, a new report says. Alleviating Hospital-Based Malnutrition: A Baseline Progress Report is an assessment of hospital-based malnutrition released in connection with the first anniversary of ...

Construction Specialties introduces wall and door protection

Construction Specialties introduces wall and door protection

Construction Specialties Inc. (C/S) has debuted a new line of wall and door protection, Acrovyn by Design and Acrovyn Doors by Design. The products embed high-resolution images and logos as ...

BioSensics launches ActivePERS fall detection

BioSensics launches ActivePERS fall detection

BioSensics has introduced ActivePERS, a personal emergency response and telemonitoring solution for seniors.